Solid Biosciences Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$366.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Solid Biosciences's estimated annual revenue is currently $10.5M per year.(i)
  • Solid Biosciences received $133.7M in venture funding in February 2018.
  • Solid Biosciences's estimated revenue per employee is $65,031
  • Solid Biosciences's total funding is $366.3M.
  • Solid Biosciences's current valuation is $155M. (January 2022}

Employee Data

  • Solid Biosciences has 161 Employees.(i)
  • Solid Biosciences grew their employee count by 31% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Solid Biosciences (Solid) is a Cambridge, MA based biotech company singularly focused on developing treatments and cures for Duchenne muscular dystrophy (DMD). Solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. Condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of DMD.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$366.3M

Total Funding

161

Number of Employees

$10.5M

Revenue (est)

31%

Employee Growth %

$155M

Valuation

N/A

Accelerator

Solid Biosciences News

2022-04-19 - Solid Biosciences Management to Host Call on April 27, 2022 to ...

Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with...

2022-04-06 - Zacks: Analysts Expect Solid Biosciences Inc. (NASDAQ:SLDB) Will ...

Three analysts have issued estimates for Solid Biosciences' earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate...

2022-03-30 - Is it Time to Dump Solid Biosciences Inc (SLDB) Stock After it Is Down 0.00% in a Week?

Solid Biosciences Inc (SLDB) stock is unchanged 0.00% over the past week and gets a Bearish rating from InvestorsObserver Sentiment...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25M16153%$152M
#2
$37.2M1614%N/A
#3
$32.1M1628%N/A
#4
$18.2M16312%$153M
#5
N/A16312%N/A

Solid Biosciences Funding

DateAmountRoundLead InvestorsReference
2015-11-04$42.5MBerceptive Advisors, LLCArticle
2017-03-31$50.0MCRA Capital ManagementArticle
2018-02-01$133.7MUndisclosedJ.P. MorganArticle